FibroGen
Monoclonal antibody and protein therapeutics for oncology and rare diseases
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Latest Form D
- $20M, Dec 2014
- Total capital
- $20M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $20M
- 1 Form D · last Dec 2014
- 143 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 24 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$20M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Frank H. ValoneExecutive OfficerNamed in SEC Form D filings
- James A. SchoeneckDirectorNamed in SEC Form D filings
- Jorma Pedro RouttiDirectorNamed in SEC Form D filings
- Julian N. SternDirectorNamed in SEC Form D filings
- Kalevi F. KurkijarviDirectorNamed in SEC Form D filings
- K. Peony H. YuExecutive OfficerNamed in SEC Form D filings
Show all 13 people
- Miguel F. MaderoDirectorNamed in SEC Form D filings
- Pat B. CotroneoExecutive OfficerNamed in SEC Form D filings
- Roberto Pedro RosenkranzDirectorNamed in SEC Form D filings
- Rory B. RiggsDirectorNamed in SEC Form D filings
- Thomas F. KearnsDirectorNamed in SEC Form D filings
- Thomas B. NeffExecutive Officer, DirectorNamed in SEC Form D filings
- Toshinari N. TamuraDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 24- PendingTreatment For Congestive Heart FailureUSPTOApplication 18728812
- PendingEnhanced Erythropoiesis And Iron MetabolismUSPTOApplication 18317195
- PendingConnective Tissue Growth Factor AntibodiesUSPTOApplication 18068977
Show all 24 patent records
- Treatment For Congestive Heart FailureMar 27, 2025 · Application 18728812Pending
- Enhanced Erythropoiesis And Iron MetabolismJun 6, 2024 · Application 18317195Pending
- Connective Tissue Growth Factor AntibodiesMar 7, 2024 · Application 18068977Pending
- Compounds, Compositions And Methods For Histone Lysine Demethylase InhibitionJan 4, 2024 · Application 18043117Pending
- Methods For Treatment Of Motor Neuron DiseasesJan 19, 2023 · Application 17688717Pending
- Methods For Treating Idiopathic Pulmonary FibrosisMay 19, 2022 · Application 17586620Pending
- Methods Of Treatment Of Muscular DystrophiesMay 12, 2022 · Application 17579581Pending
- Pharmaceutical Formulations Of A Hif Hydroxylase InhibitorFeb 24, 2022 · Application 17198013Pending
- Methods For Treating Anemia In Subjects Having Kidney Failure Using Inhibitors Of Hypoxia-inducible Factor (hif) HydroxylaseDec 2, 2021 · Application 17394602Pending
- Methods Of Treating Acute Respiratory Distress SyndromeSep 30, 2021 · Application 17217953Pending
- [(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3-CARBONYL)AMINO]ACETIC Acid (roxadustat) For The Treatment Of Chemotherapy-induced Anemia (cia)Application 63516705Pending
- Compounds, Compositions And Methods For Histone Lysine Demethylase InhibitionApplication PCTUS2022041742Pending
- ANTI-CCR8 Antibodies And Uses ThereofApplication 63399483Pending
- Modified ANTI-GALECTIN-9 Antibody And Uses ThereofApplication 63389610Pending
- ANTI-CCR8 Antibodies And Uses ThereofApplication PCTUS2023072462Pending
- Treatment For Congestive Heart FailureApplication 63306994Pending
- [(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3-CARBONYL)AMINO]ACETIC Acid (roxadustat) For The Treatment Of Anemia In Subjects With Myelodysplastic Syndrome (mds)Application 63601857Pending
- Solid [(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3-CARBONYL)AMINO]ACETIC AcidApplication PCTUS2024026159Pending
- Treatment For Congestive Heart FailureApplication 63299383Pending
- Compounds, Compositions And Methods For Histone Lysine Demethylase InhibitionApplication PCTUS2021048056Pending
- Compounds, Compositions And Methods For Histone Lysine Demethylase InhibitionApplication 63238042Pending
- Modified ANTI-GALECTIN-9 Antibody And Uses ThereofApplication PCTUS2023070259Pending
- [(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3-CARBONYL)AMINO]ACETIC Acid (roxadustat) For The Treatment Of Chemotherapy-induced Anemia (cia)Application PCTUS2024028163Pending
- Treatment For Congestive Heart FailureApplication PCTUS2023060625Pending
Related companies, and why
- Beta Cat Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Outpost Medicine, LLCSimilar federal contract value in Biotech · null in contracts
- AI Proteins, Inc.Similar federal contract value in Biotech · null in contracts
- Dialectic Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Propanc Biopharma, Inc.Similar federal contract value in Biotech · null in contracts
- CHINA PHARMA HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .